One Za’abeel’s Coveted One&Only Private Homes and ‘The Residences’ Are Now Available for Sale, Announces Ithra Dubai
8.6.2022 07:30:00 EEST | Business Wire | Press release
Ithra Dubai, a leading real estate developer and asset manager, wholly owned by Investment Corporation of Dubai, announced the highly anticipated sale of One Za’abeel’s One&Only Private Homes and The Residences in Dubai’s most iconic address.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220529005001/en/
One Za’abeel, the multi-award-winning mixed-used development, is destined to become one of the UAE’s most recognizable architectural icons located right in Dubai’s business center. A marvel of engineering with the world’s longest cantilevered building, it is set to be awarded a GUINNESS WORLD RECORD™.
Suspended perpendicularly across the two towers at a height of around 100 meters and weighing 13,000 tonnes, The Link will host several engaging experiences and will include captivating entertainment venues, dining with celebrity chefs, an infinity pool, an observation deck with uninterrupted 360˚views of Dubai, and an immersive glass-floor experience.
One Za’abeel Tower offers 94 One&Only Private Homes for sale, the pinnacle of urban living in the world’s first vertical urban resort managed by the ultra-luxury One&Only brand. Located in some of the world’s most sought-after destinations, One&Only Private Homes offer upscale private residential sanctuaries with One Za’abeel being no exception. Reflecting the architecture, design, and lifestyle elements for which One&Only is celebrated, One&Only Private Homes offer unparalleled access to the luxury hospitality collection’s world-class resorts, in addition to a series of exclusive benefits.
One Za’abeel’s The Residences houses 264 apartments with a strategic location and lavish facilities. The residences for sale include 1, 2, 3, and 4-bedroom simplexes and duplexes and a 5-bedroom penthouse.
Available for lease in this mixed-use masterpiece is deluxe office space covering an area of 26,000 square and three floors of retail space, F&B, and leisure experiences at the Podium, covering an area of 12,000 square meters.
Strategically located in the heart of the city, at the intersection of Dubai’s famous Sheikh Zayed Road and its commercial business district, One Za’abeel is the gateway to Dubai International Financial District, close to Dubai World Trade Centre, Burj Khalifa, and Dubai International Airport.
“With its mesmerizing architecture, central location, and exceptional mix of offerings, One Za’abeel is an exceptional place to live, work, and spend leisure time in one of Dubai’s most desirable addresses, a true reflection of Dubai’s ambitious spirit,” said Issam Galadari, Director and CEO of Ithra Dubai.
In line with the UAE’s net-zero target for 2050, the development aims to achieve the highest standards of sustainability as it implements the Gold LEED certification requirements in its design and functionality.
About Ithra Dubai
Ithra Dubai LLC, wholly owned by Investment Corporation of Dubai (ICD), develops and manages a portfolio of pioneering real estate projects in Dubai and in key international markets. Its projects are designed to embrace diversity, shape happy communities, and bring prosperity to many. Ithra Dubai aims to deliver mixed-used developments on an ambitious scale, which incorporates world-class retail, commercial, residential, and leisure concepts.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220529005001/en/
Contact information
Yara Bou Hadir
pressenquiries@sabaconsultants.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom